Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with Docetaxel and S-1 in Metastatic Gastric Cancer
NCT03154983Phase 2Unknown
- Start
- May 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in gastric cancer (GC). Primary endpoint: Progression-Free Survival at 30 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03154983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03154983.